Raúl P Valdez - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Raúl P Valdez

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Archivos Argentinos De Pediatria|January 28, 2020

Maritornes and geneticsRaúl P Valdez

International Journal of Dermatology|October 2, 2010

Tamoxifen vs. non-tamoxifen treatment for advanced melanoma: a meta-analysisJulieta Ruiz Beguerie, Jin Xingzhong, Raúl P Valdez

Archives of Drug Information|January 26, 2010

Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study ResultsFernando M Stengel, Valeria Petri, Gladys Am Campbell, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Archivos Argentinos De Pediatria|January 28, 2020

Maritornes and geneticsRaúl P Valdez

International Journal of Dermatology|October 2, 2010

Tamoxifen vs. non-tamoxifen treatment for advanced melanoma: a meta-analysisJulieta Ruiz Beguerie, Jin Xingzhong, Raúl P Valdez

Archives of Drug Information|January 26, 2010

Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study ResultsFernando M Stengel, Valeria Petri, Gladys Am Campbell, et al.

Pageof 1